Glycolysis and de novo fatty acid synthesis cooperatively regulate pathological vascular smooth muscle cell phenotypic switching and neointimal hyperplasia.
Kaixiang CaoTiejun ZhangZou LiMingchuan SongAnqi LiJingwei YanShuai GuoLitao WangShuqi HuangZiling LiWenzhong HouXiaoyan DaiYong WangDu FengJun HeXiaodong FuYiming XuPublished in: The Journal of pathology (2023)
Switching of vascular smooth muscle cells (VSMCs) from a contractile phenotype to a dedifferentiated (proliferative) phenotype contributes to neointima formation, which has been demonstrated to possess a tumour-like nature. Dysregulated glucose and lipid metabolism is recognized as a hallmark of tumours but has not thoroughly been elucidated in neointima formation. Here, we investigated the cooperative role of glycolysis and fatty acid synthesis in vascular injury-induced VSMC dedifferentiation and neointima formation. We found that the expression of hypoxia-inducible factor-1α (HIF-1α) and its target 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3), a critical glycolytic enzyme, were induced in the neointimal VSMCs of human stenotic carotid arteries and wire injured mouse carotid arteries. HIF-1α overexpression to elevate glycolysis resulted in a decreased contractile phenotype while promoting VSMC proliferation and mTORC1 activation. Conversely, silencing Pfkfb3 had the opposite effects. Mechanistic studies demonstrated that glycolysis generates acetyl coenzyme A to fuel de novo fatty acid synthesis and mTORC1 activation. Whole-transcriptome sequencing analysis confirmed the increased expression of PFKFB3 and fatty acid synthetase (FASN) in dedifferentiated VSMCs. More importantly, FASN upregulation was observed in neointimal VSMCs of human stenotic carotid arteries. Finally, interfering with PFKFB3 or FASN suppressed vascular injury-induced mTORC1 activation, VSMC dedifferentiation, and neointima formation. Together, this study demonstrated that PFKFB3-mediated glycolytic reprogramming and FASN-mediated lipid metabolic reprogramming are distinctive features of VSMC phenotypic switching and could be potential therapeutic targets for treating vascular diseases with neointima formation. This article is protected by copyright. All rights reserved.
Keyphrases
- smooth muscle
- fatty acid
- vascular smooth muscle cells
- endothelial cells
- high glucose
- angiotensin ii
- poor prognosis
- single cell
- diabetic rats
- cell proliferation
- signaling pathway
- binding protein
- stem cells
- genome wide
- bone marrow
- type diabetes
- tyrosine kinase
- blood glucose
- mesenchymal stem cells
- transcription factor
- cell therapy
- stress induced